BVI announced the first US implantations of its Finevision HP hydrophobic trifocal intraocular lens, marking the clinical debut of the device following regulatory clearance by the US Food and Drug Administration (FDA) in October 2025.

Finevision HP is a third-generation trifocal IOL developed through the collaboration of BVI research and development director Christophe Pagnoulle and ophthalmologist Damien Gatinel, MD, PhD,  It incorporates BVI’s POD platform and CoPODize technology, featuring a diffractive design intended to distribute light across distance, intermediate, and near focal points. The lens also features a double C-loop haptic designed to enhance in-the-bag stability.

The initial procedures were performed at multiple surgical centers by 5 cataract and refractive surgeons who serve on the company’s US Surgical Leadership Council: George O. Waring IV, MD; Nathan M. Radcliffe, MD; Nicole Fram, MD; Robert J. Weinstock, MD; and Vance Thompson, MD. According to the company, these cases represent the transition of Finevision HP from regulatory approval to real-world surgical use in the United States. The lens has been available outside the US for more than 15 years.

BVI reported that US clinical evaluation and global data have demonstrated consistent visual performance across lighting conditions. The company plans a phased rollout across select US centers, with broader availability expected during 2026. GP